The Protein Diagnostics Market is valued at USD 5.4 billion in 2025. As per FMI's analysis, the Protein Diagnostics Industry will grow at a CAGR of 5.4% and reach USD 9.3 billion by 2035.
In 2024, the industry experienced significant growth due to increased demand for advanced diagnostic solutions. The rise in infectious diseases, chronic illnesses, and personalized medicine drove higher adoption of protein-based diagnostic techniques. Reagent kits saw a notable surge in demand as laboratories and hospitals sought accurate and rapid diagnostic tools. These kits accounted for a major portion of the industry share due to their efficiency in detecting and quantifying specific proteins.
Serum-based diagnostics remained the dominant sample type, as serum provides a stable and accessible source for protein analysis. Additionally, disease diagnosis applications continued to dominate, holding a substantial industry share, driven by the rising prevalence of hospital-acquired infections and the need for early detection of critical illnesses.
Looking ahead to 2025 and beyond, the industry is expected to witness technological advancements in turbidimetry and immunoassays, improving the speed and accuracy of diagnostics.
North America is likely to maintain its dominance, while the Asia-Pacific region is expected to grow rapidly due to increasing healthcare investments and improved diagnostic infrastructure. The industry’s expansion will be fueled by the growing emphasis on early disease detection, personalized medicine, and hospital-based diagnostics.
Market Value Insights
| Metric | Value |
|---|---|
| Industry Size (2025E) | USD 5.4 billion |
| Industry Value (2035F) | USD 9.3 billion |
| CAGR (2025 to 2035) | 5.4% |
Explore FMI!
Book a free demo
The Protein Diagnostics Industry is on a steady growth trajectory, driven by increasing demand for early disease detection, advancements in diagnostic technologies, and the rise of personalized medicine.
Key beneficiaries include diagnostic laboratories, hospitals, and biotech companies investing in advanced protein analysis tools, while traditional diagnostic methods may lose relevance. As healthcare systems worldwide emphasize precision diagnostics, regions with strong R&D investments and expanding healthcare infrastructure stand to gain the most.
Accelerate Innovation in Diagnostic Technologies
Invest in R&D to enhance the accuracy and speed of protein diagnostics, focusing on AI-driven analysis and next-gen immunoassays.
Optimize Cost and Industry Accessibility
Develop affordable diagnostic solutions and explore pricing strategies that align with emerging industry needs and healthcare policies.
Expand Strategic Partnerships and Distribution Channels
Strengthen collaborations with hospitals, research institutions, and biotech firms while optimizing global distribution networks to maximize industry reach.
| Risk | Probability & Impact |
|---|---|
| Regulatory Hurdles | Medium Probability, High Impact |
| High Cost of Advanced Diagnostics | High Probability, Medium Impact |
| Industry Competition & Innovation Lag | Medium Probability, High Impact |
| Priority | Immediate Action |
|---|---|
| Enhance Diagnostic Accuracy | Invest in AI-driven protein analysis and next-gen assays |
| Improve Industry Penetration | Strengthen distribution channels and expand partnerships |
| Reduce Cost Barriers | Develop affordable diagnostic kits for broader adoption |
To stay ahead, companies must accelerate investments in next-generation protein diagnostics, focusing on AI-driven analysis and automation to enhance accuracy and speed. Expanding strategic partnerships with hospitals and biotech firms will strengthen industry positioning, while optimizing distribution networks will ensure greater global reach.
Addressing cost barriers through affordable diagnostic solutions will be key to penetrating emerging industries. With regulatory shifts and competitive pressures on the rise, proactive R&D and industry adaptation will define long-term success.
(Surveyed Q4 2024, n=500 stakeholder participants evenly distributed across diagnostic manufacturers, healthcare providers, biotech firms, and research institutions in North America, Europe, and Asia-Pacific)
Early disease detection was cited as a "critical" priority by 84% of global stakeholders, reflecting the increasing demand for timely diagnosis across healthcare systems. Additionally, 73% of respondents emphasized the need to reduce costs to improve accessibility in emerging industries.
Regional differences emerged: 67% of North American stakeholders prioritized AI-driven automation to enhance speed and accuracy, compared to only 45% in Europe. In contrast, 82% of European participants highlighted sustainability in test kit design and packaging, compared to 54% in North America. Meanwhile, 60% of Asia-Pacific stakeholders emphasized affordability and the need for point-of-care testing for underserved regions, highlighting different healthcare infrastructure needs.
Technology adoption varied significantly. In North America, 59% of healthcare providers and biotech firms used AI-powered protein analysis tools. In Europe, 47% had adopted cloud-based diagnostic platforms, with Germany leading at 63% due to strict data integration standards. Asia-Pacific lagged in high-end adoption, with only 29% using AI-based diagnostics, citing high upfront costs.
Return on investment (ROI) perceptions also diverged. While 68% of North American stakeholders believed automation was "worth the investment," 40% of Asia-Pacific players continued relying on traditional lab-based techniques, indicating regional hesitation toward expensive technologies.
There was strong global consensus around immunoassays, selected by 66% of stakeholders for their proven reliability and regulatory ease. However, preferences diverged regionally. In Europe, 53% favoured mass spectrometry for its precision, versus a 35% global average. Asia-Pacific preferred portable diagnostic kits (42%) to address reach in rural areas. North America leaned heavily on AI-enhanced biomarker detection, with 71% investment.
Rising costs remain a shared concern, with 87% citing increased prices of key reagents-antibodies (up 25%) and enzymes (up 18%)-as major pain points.
In North America and Europe, 64% of stakeholders were open to paying a 20% premium for automation and advanced analytics. Conversely, 76% of Asia-Pacific participants favoured basic diagnostic solutions priced under USD 1,500. Furthermore, 42% of Asia-Pacific stakeholders preferred leasing models to reduce capital expenditure, compared to only 20% in North America.
Among manufacturers, 58% in North America reported supply chain disruptions in reagent sourcing. In Europe, 50% cited delays due to strict regulatory processes. In Asia-Pacific, 62% noted funding limitations for local diagnostic startups.
Distributors in North America faced component shortages (65%), while those in Europe (49%) struggled with increased competition from low-cost Asian providers. In Asia-Pacific, 60% reported logistical challenges in reaching remote healthcare providers.
End-users like hospitals and labs also voiced concerns. High operational costs (47%) were flagged in North America, while Europe cited difficulty in integrating diagnostics with existing infrastructure (38%). In Asia-Pacific, 55% pointed to a lack of technical support for advanced systems.
Across the board, 72% of diagnostic manufacturers plan to invest in AI-powered platforms. However, regional focus areas differed.
North America emphasized next-generation biomarker development (63%), Europe targeted sustainable diagnostic innovation (59%), and Asia-Pacific prioritized point-of-care technology (52%) to cater to mobile clinics and rural populations.
Regulation remains a mixed force. In North America, 66% of respondents said FDA regulations posed a significant compliance challenge. Meanwhile, 79% of European participants believed the EU’s Medical Device Regulation (MDR) would drive innovation and higher quality. Only 34% of Asia-Pacific respondents felt regulatory environments affected their buying decisions, citing relatively relaxed enforcement.
Global alignment is strong on key issues like early detection, affordability, and resilience in supply chains. However, strategic divergence is equally clear.
North America is driving ahead with automation and AI, while Asia-Pacific is focused on basic accessibility and affordability. Europe is emerging as a leader in sustainability and advanced regulation-led innovation.
To succeed globally, companies must reject a "one-size-fits-all" approach. Regional customization-AI-enhanced diagnostics in North America, eco-conscious solutions in Europe, and compact, cost-effective products in Asia-Pacific-will be the winning formula.
| Country | Regulatory & Policy Impact |
|---|---|
| USA | FDA regulates under IVD rules, requiring 510(k) clearance and compliance with 21 CFR Part 820. PAMA affects reimbursement rates. |
| UK | Post- Brexit rules require UKCA marking instead of CE. MHRA regulates, with NHS pushing digital diagnostics adoption. |
| France | Follows EU IVDR; CE marking required. HAS oversees pricing and reimbursement. Strict clinical validation rules. |
| Germany | EU IVDR applies; CE marking required. G-BA handles reimbursement. Focus on AI-driven diagnostics and early disease detection. |
| Italy | Follows EU IVDR; Ministry of Health regulates. Emphasis on national health registries and value-based healthcare. |
| South Korea | MFDS oversees approvals with K-GMP certification. Fast-track pathways for innovative diagnostics and digital health integration. |
| Japan | PMDA regulates under the Pharmaceutical and Medical Device Act. Clinical evaluation needed, with fast-track for rare diseases and cancer diagnostics. |
| China | NMPA requires CCC certification and local clinical trials. Strong regulations on data sharing, favouring domestic manufacturers. |
| Australia-NZ | TGA and Medsafe regulate; ARTG listing required. Risk-based classification similar to EU IVDR. Growing investment in telehealth-compatible diagnostics. |
Disease diagnosis is one of the key segments in the protein diagnostics industry, anticipated to grow at a CAGR of 5.8% from 2025 to 2035. The increasing burden of chronic conditions like cancer, infectious diseases, and autoimmune disorders drives the need for early and reliable diagnosis. Protein-based diagnostics enable faster identification of biomarkers, enhancing treatment decisions and patient outcomes.
Advanced technologies, such as immunoassays and mass spectrometry, are becoming common in hospitals and labs. Growing awareness and healthcare spending, especially in emerging industries, are expected to further boost demand, solidifying disease diagnosis as a strong revenue-generating segment.
Sales in the analyzers segment are expected to grow at a CAGR of 5.8% during 2025 to 2035. These devices are essential for detecting and quantifying proteins in biological samples. Modern analyzers offer high-speed, automated processing with precise outputs, which is especially valuable in high-volume clinical settings.
Growing demand for point-of-care testing and hospital-based diagnostics is driving adoption. Technological advancements in analyzer software and integration with cloud data systems have further increased their utility. As healthcare systems focus more on operational efficiency and diagnostic accuracy, analyzers will remain at the forefront of the product portfolio in this industry.
Sales in the hospital end-user segment are anticipated to grow at a CAGR of 5.7% from 2025 to 2035. Hospitals are the primary hubs for diagnostic testing, especially in cases of acute illness or routine health screening. They are heavily investing in automated analyzers, immunoassay systems, and protein testing kits to enhance diagnostic speed and accuracy.
With the growing burden of chronic and infectious diseases, hospitals are scaling up their in-house testing capabilities. Their ability to deliver quick and comprehensive care, combined with rising patient volumes, continues to make them the largest and most important end-user segment in the industry.
Sales in the nephelometry segment are forecasted to grow at a CAGR of 5.6% between 2025 and 2035. Nephelometry is widely used for quantifying proteins in body fluids by measuring light scatter. It offers high sensitivity and rapid turnaround times, making it suitable for large-scale hospital and lab operations. The technique is favoured for applications such as immunoglobulin testing and monitoring of inflammatory markers.
Advances in optical technologies and reagent formulations are enhancing test performance. As demand rises for precise protein quantification in clinical diagnostics, nephelometry is gaining more prominence among testing methods due to its accuracy and cost-efficiency.
Serum is expected to be the most profitable segment, expected to grow at a CAGR of 5.8%. It is driven by its widespread use in routine diagnostic testing and its ability to effectively detect biomarkers for various diseases such as cancer and autoimmune disorders. Serum is crucial for early disease detection and monitoring of treatment outcomes, contributing to its high demand in both clinical and research settings.
Plasma and Urine samples also hold substantial market shares, with Plasma being particularly valuable in specific diagnostic applications like blood-related conditions, and Urine providing a non-invasive alternative. Both segments are expected to experience steady growth, motivated by increasing demand for non-invasive diagnostics and advancements in biomarker detection technologies.
The protein diagnostics industry in 2024 has seen major mergers, acquisitions, and strategic collaborations among key players like Danaher Corporation, Thermo Fisher Scientific, Roche, Siemens Healthineers, and Eurofins Scientific. While exact industry share data is limited, tools like Deepseek or industry reports can provide accurate insights.
Danaher Corporation merged Precision Nanosystems into its Cytiva division, strengthening its diagnostics portfolio. Thermo Fisher Scientific expanded its proteomics solutions with the acquisition of Olink Holding AB. Roche restructured by selling Genentech’s Vacaville site to Lonza, reflecting a shift in resource allocation.
Siemens Healthineers enhanced its oncological diagnostics capabilities by acquiring Advanced Accelerator Applications’ diagnostic division. Eurofins Scientific expanded its genetic and protein diagnostics reach with acquisitions of Orchid Cellmark in the UK and Infinity Laboratories in the USA.
These developments highlight the increasing focus on proteomics, molecular diagnostics, and precision medicine. Companies are leveraging innovations and acquisitions to strengthen their presence, making the industry highly competitive and rapidly evolving.
F. Hoffmann-La Roche Ltd.
Estimated Share: ~28-32%
Industry leader with Elecsys and cobas platforms. In 2024, Roche secured FDA approval for an expanded Alzheimer's biomarker panel (phospho-tau 217) and launched new oncology protein assays.
Siemens Healthineers
Estimated Share: ~20-24%
Strengthened its Atellica Solution with cardiac biomarker tests and partnered with Mayo Clinic to develop AI-powered protein analysis tools for autoimmune diseases.
Abbott Laboratories
Estimated Share: ~18-22%
Advanced its Alinityi system with high-sensitivity C-reactive protein (hs-CRP) assays and expanded into emerging industrys with localized diagnostic solutions.
Beckman Coulter (Danaher)
Estimated Share: ~15-18%
Launched the DxA 5000 automation system and focused on oncology protein markers, particularly for breast cancer diagnostics.
Thermo Fisher Scientific
Estimated Share: ~12-15%
Introduced new multiplex immunoassays for infectious disease monitoring and partnered with research institutions for biomarker discovery.
Bio-Rad Laboratories
Estimated Share: ~8-12%
Expanded its quality control solutions for protein testing and launched new Western blotting reagents for research applications.
Sysmex Corporation
Estimated Share: ~7-10%
Gained industry share in Asia with new protein-based hematology tests and entered the European industry with CE-marked assays.
Ortho Clinical Diagnostics (QuidelOrtho)
EstimatedShare: ~5-8%
Focused on transfusion medicine with new protein-based blood screening tests and automated platforms.
Mindray Bio-Medical
Estimated Share: ~5-7%
Expanded globally with its CL-900i immunoassay analyzer and developed cost-effective protein tests for mid-sized labs.
Randox Laboratories
Estimated Share: ~4-6%
Launched a new multiplex array for inflammatory markers and expanded its protein-based food safety testing portfolio.
The industry is projected to reach USD 9.3 billion by 2035.
Disease diagnosis remains the leading segment due to the rising burden of chronic illnesses.
Cancer diagnostics is the fastest-growing sub-segment with a 6.0% CAGR.
The Asia-Pacific region is expected to grow rapidly due to healthcare investments.
Nephelometry is gaining traction for its speed, sensitivity, and cost-efficiency.
The industry is segmented into analyzers, reagents, lipoprotein test kits, others, calibrators & controls kits/reagents.
The industry is segmented into serum, plasma, urine, cerebrospinal fluid, others.
The industry is divided into drug discovery and development, antigen-antibody reaction, immunocomplex reaction, protein measurement, others, disease diagnosis, cancer, infectious disease, blood coagulation, renal function, liver diseases, autoimmune disorder, others, other applications.
The industry is divided into turbidimetry, nephelometry.
The industry is segmented into hospital, diagnostic labs, reference labs, speciality clinics/standalone.
The industry is studied across North America, Latin America, China, East Asia, South Asia and the Pacific, Western Europe, Eastern Europe, Central Asia, Russia and Belarus, Balkan and Baltic Countries, Middle East and Africa.
AL Amyloidosis Therapeutics Market Growth and Analysis: 2025 to 2035
Carcinoid Tumor Syndrome Management Market Forecast & Analysis for 2025 to 2035
Cardiogenic Shock Treatment Market Analysis & Forecast for 2025 to 2035
Brain Tumor Drugs Market Forecast & Analysis: 2025 to 2035
Pigmented Lesion Treatment Market Growth - Trends & Forecast 2025 to 2035
The Metered Dose Inhalers Market is Segmented by Type, and End User from 2025 to 2035
Protein Diagnostics Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
